DiagnaMed Holdings Corp. (TSE:DMED)
:DMED
Top Page
No summary available
Positive Factors
FDA Orphan Drug Designation
This designation provides tax credits and market exclusivity, enhancing DiagnaMed's ability to accelerate development programs and potentially improving its market position in rare disease therapeutics.
Negative Factors
Zero Revenue
The inability to generate revenue indicates significant challenges in market penetration and product monetization, threatening long-term financial sustainability and growth potential.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA Orphan Drug Designation
This designation provides tax credits and market exclusivity, enhancing DiagnaMed's ability to accelerate development programs and potentially improving its market position in rare disease therapeutics.
Read all positive factors
DiagnaMed Holdings Corp. (DMED) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$11.43M
Dividend YieldN/A
Average Volume (3M)717.73K
Price to Earnings (P/E)―
Beta (1Y)2.10
Revenue GrowthN/A
EPS Growth-67.11%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding114,267,300
10 Day Avg. Volume538,664
30 Day Avg. Volume717,725
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-3.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DiagnaMed Holdings Corp. Business Overview & Revenue Model
Company Description
Diagnamed Holdings Corp. engages in developing a platform of software-based prescription digital therapeutic products for detecting brain age and tremors for neurological disorders. The company is headquartered in Vancouver, Canada....
How the Company Makes Money
DiagnaMed Holdings Corp. generates revenue primarily through the sale of its diagnostic and monitoring solutions to healthcare providers, clinics, and hospitals. The company employs a revenue model that includes direct sales of its proprietary dev...
DiagnaMed Holdings Corp. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -24.71K | -16.05K |
| EBITDA | -1.00M | -501.00K | -100.00K | -1.13M | -1.95M |
| Net Income | -891.75K | -501.00K | -1.28M | -1.13M | -1.95M |
Balance Sheet | |||||
| Total Assets | 167.31K | 201.75K | 662.27K | 1.62M | 2.39M |
| Cash, Cash Equivalents and Short-Term Investments | 128.41K | 162.15K | 606.96K | 1.57M | 2.36M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 439.95K | 466.91K | 426.38K | 369.51K | 150.24K |
| Stockholders Equity | -272.65K | -265.17K | 235.89K | 1.25M | 2.24M |
Cash Flow | |||||
| Free Cash Flow | -531.46K | -444.82K | -1.07M | -787.58K | -565.60K |
| Operating Cash Flow | -531.46K | -444.82K | -1.07M | -787.58K | -565.60K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 34.07K |
| Financing Cash Flow | 623.17K | 0.00 | 104.25K | 0.00 | 2.89M |
DiagnaMed Holdings Corp. Technical Analysis
Positive
0.10
Price Trends
0.10
Positive
0.09
Positive
0.08
Positive
Market Momentum
>-0.01
Positive
46.96
Neutral
28.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DMED, the sentiment is Positive. The current price of 0.1 is below the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.10, and above the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.96 is Neutral, neither overbought nor oversold. The STOCH value of 28.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DMED.
DiagnaMed Holdings Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | C$11.43M | -21.40 | 527.45% | ― | ― | -67.11% | |
53 Neutral | C$14.18M | -11.57 | ― | ― | 16.04% | -455.38% | |
48 Neutral | C$50.13M | -2.31 | -207.53% | ― | ― | 7.04% | |
45 Neutral | C$33.11M | -9.48 | 3086.87% | ― | -48.53% | -9.66% | |
42 Neutral | C$8.20M | -5.12 | 6239.15% | ― | ― | 48.94% | |
42 Neutral | C$6.67M | -4.68 | ― | ― | ― | 81.01% |
* Healthcare Sector Average
TSE:DMED
DiagnaMed Holdings Corp.
0.10
0.08
300.00%
TSE:ADK
Diagnos
0.28
<0.01
1.85%
TSE:AIDR
Rocket Doctor AI
0.59
0.19
49.37%
TSE:CHS
Comprehensive Healthcare Systems Inc
0.79
0.49
163.33%
TSE:UDOC
UniDoc Health Corp
0.10
-0.22
-69.35%
TSE:NARA
PanGenomic Health, Inc. Class A
0.48
0.27
126.19%
DiagnaMed Holdings Corp. Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
DiagnaMed Expands Natural Hydrogen Portfolio with Strategic Acquisition in Nova Scotia
Positive
Dec 10, 2025
DiagnaMed Holdings Corp. has entered into an acquisition agreement to acquire the Colchester East Natural Hydrogen Project in Nova Scotia, which consists of 30 licenses totaling 2,104 claims. This strategic move places DiagnaMed in a prominent pos...
Business Operations and Strategy
DiagnaMed Expands Hydrogen Zone in Ontario’s Témiscamingue Graben
Positive
Oct 27, 2025
DiagnaMed Holdings Corp., in collaboration with Québec Innovative Materials Corp., has announced a significant expansion of the natural hydrogen system in Ontario’s Témiscamingue Graben by over 11 kilometers. The soil-gas survey re...
Business Operations and Strategy
DiagnaMed and QIMC Unveil Major Natural Hydrogen Discovery in Ontario
Positive
Oct 14, 2025
DiagnaMed Holdings Corp. and Québec Innovative Materials Corp. have announced a significant natural hydrogen discovery in Ontario’s Témiscamingue Graben, marking a pivotal development in their clean-tech initiatives. This discovery...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―